AACR 2024 – presenting ovarian cancer patient-specific drug responses to PARPi and immunotherapies
28 March 2024
VitroScan’s Willemijn Vader is proud to present our ex vivo micro tumor testing study for the classification of ovarian cancer patient-specific sensitivity to PARPi and immunotherapies, both as monotherapy and in combination, at the AACR Annual Meeting 2024!
This study is performed in collaboration with the study teams of the Leiden University Medical Center (Cor de Kroon, Judith Kroep), Radboud University Medical Center (Anne van Altena, Nelleke Ottevanger), Oncodia (Kristofer Maad), and supported by …
Meet us to discover our newest advancements and discuss collaborative opportunities.
Find the abstract via: 3726 / 12 - Absence of synergistic effects for PARPi and immunotherapy combinations in ex vivo 3D micro tumor assay for ovarian cancer patients